Teva Pharmaceutical Industries Ltd., announces the commercial availability of a liquid formulation of its anti-cancer drug, Treanda (bendamustine HCI) injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced.

Treanda is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first-line therapies other than chlorambucil has not been established. It is also indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Source: Teva Pharmaceutical Industries